Ubiquitin/Ubl System Targeted Compound News from the Clinic

 

Clinical trials update from clinicaltrials.gov

Millennium’s proteasome inhibitor Velcade (Bortezomib).
Uploaded: 13 February 2012

‘Ubiquitin’-related activity.
Uploaded: 13 February 2012

Millennium’s NEDD8 E1 inhibitor MLN4924.
Uploaded: 13 February 2012

 

VELCADE®

Official Website
Uploaded: 20 July 2012

VELCADE® receives FDA Approval for subcutaneous administration
Uploaded: 20 July 2012

 

Carfilzomib

On July 20, 2012, the U. S. FDA granted accelerated approval to carfilzomib injection for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of the completion of the last therapy.
Uploaded: 20 July 2012

Kyprolis™ (proposed tradename for carfilzomib)
Uploaded: 20 July 2012

Clinical trials update from clinicaltrials.gov: Onyx’sProteasome inhibitor Carfilzomib.
Uploaded: 20 July 2012

 

ONX 0914

ONX 0914 is an immunoproteasome inhibitor with potential treatment applications in autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease and lupus.
Uploaded: 20 July 2012

ONX 0914 is being investigated in preclinical studies in autoimmune disorders (rheumatoid arthritis, inflammatory bowel disease, and lupus)
Uploaded: 20 July 2012

 

Other Documents of Interest

ITI Life Sciences (2007): Emerging drug targets: Ubiquitin signalling – market foresighting.
Uploaded: 13 February 2012